Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 36
Filter
1.
Int J Mol Sci ; 24(14)2023 Jul 08.
Article in English | MEDLINE | ID: mdl-37510995

ABSTRACT

Glycine is a non-essential amino acid with many functions and effects. Glycine can bind to specific receptors and transporters that are expressed in many types of cells throughout an organism to exert its effects. There have been many studies focused on the anti-inflammatory effects of glycine, including its abilities to decrease pro-inflammatory cytokines and the concentration of free fatty acids, to improve the insulin response, and to mediate other changes. However, the mechanism through which glycine acts is not clear. In this review, we emphasize that glycine exerts its anti-inflammatory effects throughout the modulation of the expression of nuclear factor kappa B (NF-κB) in many cells. Although glycine is a non-essential amino acid, we highlight how dietary glycine supplementation is important in avoiding the development of chronic inflammation.


Subject(s)
Glycine , Trace Elements , Humans , Glycine/pharmacology , Glycine/therapeutic use , Micronutrients/therapeutic use , Cytokines/metabolism , NF-kappa B/metabolism , Amino Acids , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Inflammation/drug therapy , Inflammation/metabolism , Trace Elements/therapeutic use
2.
Curr Vasc Pharmacol ; 20(3): 221-229, 2022.
Article in English | MEDLINE | ID: mdl-35864795

ABSTRACT

Glycine Receptors (GlyRs) are cell-surface transmembrane proteins that belong to the Cysloop ligand-gated ion channels superfamily (Cys-loop LGICs). Functional glycine receptors are conformed only by α-subunits (homomeric channels) or by α- and ß-subunits (heteromeric channels). The role of glycine as a cytoprotective is widely studied. New information about glycine modulation of vascular endothelial cells (ECs) function emerged last year. Glycine and its receptors are recognized to play a role as neurovascular protectors by a mechanism that involves α2GlyRs. Interestingly, the expression of α2GlyRs reduces after stroke injury. However, glycine reverses the inhibition of α2GlyRs by a mechanism involving the VEGF/pSTAT3 signaling. On the other hand, consistent evidence has demonstrated that ECs participate actively in the innate and adaptive immunological response. We recently reported that GlyRs are modulated by interleukin-1ß, suggesting new perspectives to explain the immune modulation of vascular function in pathological conditions such as cerebrovascular stroke. In this work, we distinguish the role of glycine and the allosteric modulation of glycine receptors as a new therapeutic target to confront post-ischemic injury.


Subject(s)
Ligand-Gated Ion Channels , Receptors, Glycine , Endothelial Cells/metabolism , Endothelium, Vascular/metabolism , Glycine/metabolism , Glycine/pharmacology , Glycine/therapeutic use , Humans , Interleukin-1beta/metabolism , Ligand-Gated Ion Channels/metabolism , Receptors, Glycine/metabolism , Vascular Endothelial Growth Factor A/metabolism
3.
Int J Mol Sci ; 21(6)2020 Mar 20.
Article in English | MEDLINE | ID: mdl-32244885

ABSTRACT

Colorectal cancer (CRC) is one of the most widespread and deadly types of neoplasia around the world, where the inflammatory microenvironment has critical importance in the process of tumor growth, metastasis, and drug resistance. Despite its limited effectiveness, 5-fluorouracil (5-FU) is the main drug utilized for CRC treatment. The combination of 5-FU with other agents modestly increases its effectiveness in patients. Here, we evaluated the anti-inflammatory Trimethylglycine and the Signal transducer and activator of transcription (STAT6) inhibitor AS1517499, as possible adjuvants to 5-FU in already established cancers, using a model of colitis-associated colon cancer (CAC). We found that these adjuvant therapies induced a remarkable reduction of tumor growth when administrated together with 5-FU, correlating with a reduction in STAT6-phosphorylation. This reduction upgraded the effect of 5-FU by increasing both levels of apoptosis and markers of cell adhesion such as E-cadherin, whereas decreased epithelial-mesenchymal transition markers were associated with aggressive phenotypes and drug resistance, such as ß-catenin nuclear translocation and Zinc finger protein SNAI1 (SNAI1). Additionally, Il-10, Tgf-ß, and Il-17a, critical pro-tumorigenic cytokines, were downmodulated in the colon by these adjuvant therapies. In vitro assays on human colon cancer cells showed that Trimethylglycine also reduced STAT6-phosphorylation. Our study is relatively unique in focusing on the effects of the combined administration of AS1517499 and Trimethylglycine together with 5-FU on already established CAC which synergizes to markedly reduce the colon tumor load. Together, these data point to STAT6 as a valuable target for adjuvant therapy in colon cancer.


Subject(s)
Adjuvants, Pharmaceutic/therapeutic use , Carcinogenesis/pathology , Colitis/complications , Colonic Neoplasms/drug therapy , Fluorouracil/therapeutic use , Glycine/therapeutic use , Pyrimidines/therapeutic use , STAT6 Transcription Factor/metabolism , Adjuvants, Pharmaceutic/pharmacology , Animals , Apoptosis/drug effects , Cadherins/metabolism , Cell Adhesion Molecules/metabolism , Cell Line, Tumor , Cell Nucleus/drug effects , Cell Nucleus/metabolism , Cell Survival/drug effects , Colitis/pathology , Colonic Neoplasms/etiology , Colonic Neoplasms/pathology , Cytokines/metabolism , Epithelial Cells/drug effects , Epithelial Cells/metabolism , Epithelial Cells/pathology , Female , Fluorouracil/pharmacology , Glycine/pharmacology , Humans , Inflammation/pathology , Mice, Inbred BALB C , Monocytes/metabolism , Phosphorylation/drug effects , Pyrimidines/pharmacology , beta Catenin/metabolism
4.
Nitric Oxide ; 93: 90-101, 2019 12 01.
Article in English | MEDLINE | ID: mdl-31604145

ABSTRACT

The mechanisms underlying temporomandibular disorders following orofacial pain remain unclear. Hydrogen sulfide (H2S), a newly identified gasotransmitter, has been reported to modulate inflammation. Cystathionine γ-lyase (CSE) is responsible for the systemical production of H2S, which exerts both pro- and antinociceptive effects through inflammation. In the current study, we investigated whether the endogenous H2S production pathway contributes to arousal and maintenance of orofacial inflammatory pain, through the investigation of the effects of a CSE inhibitor, propargyglycine (PAG), in a rat CFA (Complete Freund Adjuvant)-induced temporomandibular inflammation model to mimic persistent pain in the orofacial region. For this, rats received either CFA or saline in the temporomandibular joints (TMJs), and after 3 or 14 days, they received a single injection of PAG or saline and were evaluated for nociception with the von Frey and formalin test. Also, pro-inflammatory cytokines, tumor necrosis factor-α (TNF-α), and interleukin-1ß (IL-1ß) were analyzed in TMJs and trigeminal ganglion (TG). In this last one, glial cells reactivity was also verified. Endogenous H2S production rate were measured in both, TMJ and TG. Our results indicated decreased allodynia and hyperalgesic responses in rats submitted to CFA after injection of PAG. Moreover, PAG inhibited leucocyte migration to temporomandibular synovial fluid after 3 and 14 days of inflammation. PAG was able to reduce levels of CBS, CSE, TNF-α, and IL-1ß in the TMJ and TG, after 13 days of CFA injection. The observed increased activation of glial cells in the trigeminal ganglia on the 14th day of inflammation can be prevented by the highest dose of PAG. Finally, CBS and CSE expression, and endogenous H2S production rate in the TMJ and TG was found higher in rats with persistent temporomandibular inflammation compared to rats injected with saline and PAG was able to prevent this elevation. Our results elucidated the molecular mechanisms by which H2S exerts its pro-inflammatory and pro-nociceptive role in the orofacial region by alterations in both local tissue and TG.


Subject(s)
Alkynes/therapeutic use , Glycine/analogs & derivatives , Hydrogen Sulfide/metabolism , Hyperalgesia/drug therapy , Inflammation/metabolism , Pain/drug therapy , Temporomandibular Joint/metabolism , Animals , Cystathionine gamma-Lyase/antagonists & inhibitors , Enzyme Inhibitors/therapeutic use , Glycine/therapeutic use , Interleukin-1beta/metabolism , Male , Neuroglia/drug effects , Rats, Wistar , Trigeminal Ganglion/cytology , Trigeminal Ganglion/metabolism , Tumor Necrosis Factor-alpha/metabolism
5.
Nutrients ; 10(10)2018 Oct 12.
Article in English | MEDLINE | ID: mdl-30322002

ABSTRACT

Oral mucositis is frequently a toxic effect of chemotherapeutic and/or radiotherapeutic treatment, resulting from complex multifaceted biological events involving DNA damage. The clinical manifestations have a negative impact on the life quality of cancer patients. Preventive measures and curative treatment of mucositis are still not well established. The glycine has anti-inflammatory, immunomodulatory, and cytoprotective actions, being a potential therapeutic in mucositis. The objective was to evaluate the effects of glycine on the expression of collagen and growth factors, platelet and epidermal in a hamster model oral mucositis. The mucositis was induced by the protocol of Sonis. There were 40 hamsters used, divided into two groups: Group I-control; Group II-supplemented with 5% intraperitoneal glycine, 2.0 mg/g diluted in hepes. Histopathological sections were used to perform the immune-histochemical method, the evaluation of collagen expression, and the growth factors: Epidermal growth factor (EGF) and platelet (PDGF). It was observed that the group supplemented with glycine experienced higher amounts of collagen expression and predominance type of collagen I. The glycine group presented lower immunoexpression of the growth factors, EGF and PDGF. The group supplemented with glycine showed a marked healing process of the oral mucosite, demonstrated by the predominance of collagen type I and reduction of growth factors, EGF and PDGF.


Subject(s)
Collagen Type I/metabolism , Epidermal Growth Factor/metabolism , Glycine/therapeutic use , Mouth Mucosa/drug effects , Platelet-Derived Growth Factor/metabolism , Stomatitis/drug therapy , Wound Healing/drug effects , Animals , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Cricetinae , Dietary Supplements , Female , Glycine/pharmacology , Mouth Mucosa/pathology , Stomatitis/metabolism
6.
Physiol Behav ; 188: 128-133, 2018 05 01.
Article in English | MEDLINE | ID: mdl-29425970

ABSTRACT

Hydrogen sulfide (H2S) is an endogenous neuromodulator produced mainly by the enzyme cystathionine gamma-lyase (CSE) in peripheral tissues. A pronociceptive role of endogenously produced H2S has been previously reported by our group in a model of orofacial inflammatory pain. Using the established persistent orofacial pain rat model induced by complete Freund's adjuvant (CFA) injection into temporomandibular joint (TMJ), we have now investigated the putative role of endogenous H2S modulating hypernociceptive responses. Additionally, plasmatic extravasation on TMJ was measured following different treatments by Evans blue dye quantification. Thus, rats were submitted to Von Frey and Formalin tests in orofacial region before and after pharmacological inhibition of the CSE-H2S system combined or not with CFA-induced TMJ inflammation. Pretreatment with CSE inhibitor, propargylglycine (PAG; 88.4 µmol/kg) reduced temporomandibular inflammatory pain when injected locally as well as systemically. In particular, local PAG injection seems to be more effective for hypernociceptive responses in orofacial persistent inflammation since its action is evidenced in the majority analyzed periods of the inflammatory process compared to its systemic use. Moreover, local injection seems to act on temporomandibular vascular permeability, evidenced by decreased plasmatic extravasation induced by local PAG administration. Our data are consistent with the notion that the endogenous synthetized gas H2S modulates persistent orofacial pain responses revealing the pharmacological importance of the CSE inhibitor as a possible therapeutic target for their control.


Subject(s)
Cystathionine gamma-Lyase/metabolism , Facial Pain/enzymology , Facial Pain/etiology , Inflammation/complications , Inflammation/pathology , Temporomandibular Joint/pathology , Alkynes/therapeutic use , Analysis of Variance , Animals , Enzyme Inhibitors/therapeutic use , Facial Pain/complications , Facial Pain/drug therapy , Freund's Adjuvant/toxicity , Glycine/analogs & derivatives , Glycine/therapeutic use , Hyperalgesia/drug therapy , Hyperalgesia/etiology , Inflammation/chemically induced , Male , Pain Measurement , Rats , Rats, Wistar , Time Factors , Treatment Outcome
7.
Exp Parasitol ; 169: 43-50, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27373431

ABSTRACT

The exposure of wildlife and humans to toxic residues of Roundup(®) through agricultural practices or the food chain has been reported since the herbicide was found contaminating rivers. Glyphosate, N-(phosphonomethyl)glycine acid, is a nonselective post-emergent herbicide and is formulated as an isopropylamine salt with the surfactant taloamine polyethoxylate (POEA) representing the commercial formulation of Roundup(®). There is little knowledge about the effects of the herbicide on helminth parasites, particularly those whose life cycle is related to water bodies. Here we investigated the effects of the Roundup(®) on the food-borne trematode Echinostoma paraensei in experimental conditions using different developmental stages (eggs, miracidia, cercariae, metacercariae, newly excysted larvae (NEL), helminths at seven days and helminths at fourteen days). Three different herbicide concentrations were tested based on concentrations typically applied in the field: 225, 450 and 900 mg/L. Specimens were analyzed in vitro for hatching miracidia, mortality and excystment rate of metacercariae and in vivo for parasitic load and egg production. There was a significant difference in the hatching miracidia rate only for the newly embryonated eggs. The mortality of specimens and excystment rate of metacercariae were concentration-dependent. There was a significant difference in the miracidia mortality with respect to concentration until 56.3 mg/L. The same effect was observed for cercariae, and mortality was observed from 15 min onwards at concentrations of 225-900 mg/L. At low concentrations, mortality was detected after 30 min. The effects of the herbicide concentration on NEL and on helminths at seven and fourteen days showed a significant difference after 24 h. There was no significant difference in parasitic load and egg production after infection of rodents with exposed metacercariae. All developmental stages of the trematode E. paraensei were affected by Roundup(®) exposure under experimental conditions. These results suggest that dynamics of transmission of the trematode could be affected in the natural environments. The study also reinforces the usefulness of this trematode as a good model organism to test pesticides regarding human and environmental health.


Subject(s)
Echinostoma/drug effects , Echinostomiasis/drug therapy , Enzyme Inhibitors/pharmacology , Glycine/analogs & derivatives , Herbicides/pharmacology , Life Cycle Stages/drug effects , Animals , Biomphalaria , Cricetinae , Echinostoma/growth & development , Echinostoma/physiology , Echinostomiasis/parasitology , Enzyme Inhibitors/therapeutic use , Female , Glycine/pharmacology , Glycine/therapeutic use , Herbicides/therapeutic use , Mesocricetus , Oviposition/drug effects , Parasite Load , Sigmodontinae , Time Factors , Glyphosate
8.
Braz J Med Biol Res ; 48(7): 622-8, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25945746

ABSTRACT

Posthemorrhagic shock mesenteric lymph (PHSML) is a key factor in multiple organ injury following hemorrhagic shock. We investigated the role of hydrogen sulfide (H2S) in PHSML drainage in alleviating acute kidney injury (AKI) by administering D,L-propargylglycine (PPG) and sodium hydrosulfide hydrate (NaHS) to 12 specific pathogen-free male Wistar rats with PHSML drainage. A hemorrhagic shock model was established in 4 experimental groups: shock, shock+drainage, shock+drainage+PPG (45 mg/kg, 0.5 h prehemorrhage), and shock+drainage+NaHS (28 µmol/kg, 0.5 h prehemorrhage). Fluid resuscitation was performed after 1 h of hypotension, and PHMSL was drained in the last three groups for 3 h after resuscitation. Renal function and histomorphology were assessed along with levels of H2S, cystathionine-γ-lyase (CSE), Toll-like receptor 4 (TLR4), interleukin (IL)-10, IL-12, and tumor necrosis factor (TNF)-α in renal tissue. Hemorrhagic shock induced AKI with increased urea and creatinine levels in plasma and higher H2S, CSE, TLR4, IL-10, IL-12, and TNF-α levels in renal tissue. PHSML drainage significantly reduced urea, creatinine, H2S, CSE, and TNF-α but not TLR4, IL-10, or IL-12. PPG decreased creatinine, H2S, IL-10, and TNF-α levels, but this effect was reversed by NaHS administration. In conclusion, PHSML drainage alleviated AKI following hemorrhagic shock by preventing increases in H2S and H2S-mediated inflammation.


Subject(s)
Acute Kidney Injury/prevention & control , Drainage/methods , Gasotransmitters/therapeutic use , Hydrogen Sulfide/therapeutic use , Lymph/physiology , Shock, Hemorrhagic/therapy , Acute Kidney Injury/physiopathology , Alkynes/therapeutic use , Animals , Creatinine/blood , Cystathionine gamma-Lyase/analysis , Cytokines/analysis , Enzyme Inhibitors/therapeutic use , Enzyme-Linked Immunosorbent Assay , Gasotransmitters/analysis , Glycine/analogs & derivatives , Glycine/therapeutic use , Hydrogen Sulfide/analysis , Male , Mesentery , Rats, Wistar , Reproducibility of Results , Shock, Hemorrhagic/complications , Sulfites/therapeutic use , Time Factors , Treatment Outcome , Urea/blood
9.
Am J Clin Nutr ; 101(1): 210-7, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25527765

ABSTRACT

BACKGROUND: Food fortification is one approach for addressing anemia, but information on program effectiveness is limited. OBJECTIVE: We evaluated the impact of Costa Rica's fortification program on anemia in women aged 15-45 y and children aged 1-7 y. DESIGN: Reduced iron, an ineffective fortificant, was replaced by ferrous fumarate in wheat flour in 2002, and ferrous bisglycinate was added to maize flour in 1999 and to liquid and powdered milk in 2001. We used a one-group pretest-posttest design and national survey data from 1996 (baseline; 910 women, 965 children) and 2008-2009 (endline; 863 women, 403 children) to assess changes in iron deficiency (children only) and anemia. Data were also available for sentinel sites (1 urban, 1 rural) for 1999-2000 (405 women, 404 children) and 2008-2009 (474 women, 195 children), including 24-h recall data in children. Monitoring of fortification levels was routine. RESULTS: Foods were fortified as mandated. Fortification provided about one-half the estimated average requirement for iron in children, mostly and equally through wheat flour and milk. Anemia was reduced in children and women in national and sentinel site comparisons. At the national level, anemia declined in children from 19.3% (95% CI: 16.8%, 21.8%) to 4.0% (95% CI: 2.1%, 5.9%) and in women from 18.4% (95% CI: 15.8%, 20.9%) to 10.2% (95% CI: 8.2%, 12.2%). In children, iron deficiency declined from 26.9% (95% CI: 21.1%, 32.7%) to 6.8% (95% CI: 4.2%, 9.3%), and iron deficiency anemia, which was 6.2% (95% CI: 3.0%, 9.3%) at baseline, could no longer be detected at the endline. CONCLUSIONS: A plausible impact pathway suggests that fortification improved iron status and reduced anemia. Although unlikely in the Costa Rican context, other explanations cannot be excluded in a pre/post comparison.


Subject(s)
Anemia, Iron-Deficiency/prevention & control , Ferrous Compounds/therapeutic use , Food, Fortified , Glycine/therapeutic use , Iron, Dietary/therapeutic use , Mandatory Programs , Nutrition Policy , Adolescent , Adult , Anemia, Iron-Deficiency/blood , Anemia, Iron-Deficiency/diet therapy , Anemia, Iron-Deficiency/epidemiology , Animals , Child , Child, Preschool , Costa Rica/epidemiology , Female , Ferrous Compounds/administration & dosage , Glycine/administration & dosage , Hemoglobins/analysis , Humans , Infant , Iron, Dietary/administration & dosage , Male , Middle Aged , Nutrition Surveys , Prevalence , Program Evaluation , Sentinel Surveillance , Young Adult
10.
Anat Rec (Hoboken) ; 298(3): 538-45, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25156668

ABSTRACT

Tendinopathy of the Achilles tendon is a clinical problem that motivates the scientific community to search for treatments that assist in restoring its functional properties. Glycine has broad biological effects, acting as a modulator of the inflammatory cascade, and is the predominant amino acid in collagen. A 5% glycine diet provided beneficial effects against toxicity and inflammation since glycine may restructure the collagen molecules faster due to its broad anti-inflammatory effects. The purpose was analyze the effects of a 5% glycine diet in rats as a treatment for the inflammatory process. The experimental groups were as follows: C (control group), G1 and G3 (inflammatory group), and G2 and G4 (glycine+inflammatory group). G1 and G2 were euthanized 8 days following injury, and G3 and G4 were euthanized 22 days following injury. The concentrations of hydroxyproline, non-collagenous proteins, and glycosaminoglycans, as well as the activity of MMP-2 and -9 were analyzed. Biomechanical and morphological tests were employed. Higher concentrations of hydroxyproline and glycosaminoglycans were found in G4 and an increased activity of MMP-2 was found in G2. Higher birefringence was noted in group G2. The biomechanical results indicated that the tendon was more resistant to loading to rupture upon treatment with a glycine diet in group G4. Glycine induced the synthesis of important components of the tendon. A rapid remodeling was noted when compared with the inflamed-only groups. These data suggest that glycine may be a beneficial supplement for individuals with inflammation of the Achilles tendon.


Subject(s)
Achilles Tendon/drug effects , Glycine/therapeutic use , Tendinopathy/diet therapy , Animals , Dietary Supplements , Glycine/drug effects , Male , Rats, Wistar
11.
Cell Physiol Biochem ; 27(1): 13-22, 2011.
Article in English | MEDLINE | ID: mdl-21325817

ABSTRACT

BACKGROUND/AIMS: Flow restoration to ischemic myocardium reduces infarct size (IS), but it also promotes reperfusion injury. A burst of reactive oxygen species (ROS) and/or NHE-1 reactivation were proposed to explain this injury. Our study was aimed to shed light on this unresolved issue. METHODS: Regional infarction (40 min-ischemia/2 hs-reperfusion) was induced in isolated and perfused rat hearts. Maximal doses of N-(2-mercaptopropionyl)-glycine (MPG 2mmol/L, ROS scavenger), cariporide (10µmol/L, NHE-1 inhibitor), or sildenafil (1µmol/L, phosphodiesterase5A inhibitor) were applied at reperfusion onset. Their effects on IS, myocardial concentration of thiobarbituric acid reactive substances (TBARS), ERK1/2, p90(RSK), and NHE-1 phosphorylation were analyzed. RESULTS: All treatments decreased IS ∼ 50% vs. control. No further protection was obtained by combining cariporide or MPG with sildenafil. Myocardial TBARS increased after infarction and were decreased by MPG or cariporide, but unaffected by sildenafil. In line with the fact that ROS induce MAPK-mediated NHE-1 activation, myocardial infarction increased ERK1/2, p90(RSK), and NHE-1 phosphorylation. MPG and cariporide cancelled these effects. Sildenafil did not reduce the phosphorylated ERK1/2-p90(RSK) levels but blunted NHE-1 phosphorylation suggesting a direct dephosphorylating action. CONCLUSIONS: 1) Reperfusion injury would result from ROS-triggered MAPK-mediated NHE-1 phosphorylation (and reactivation) during reperfusion; 2) sildenafil protects the myocardium by favouring NHE-1 dephosphorylation and bypassing ROS generation.


Subject(s)
Myocardial Reperfusion Injury/metabolism , Reactive Oxygen Species/metabolism , Sodium-Hydrogen Exchangers/metabolism , Animals , Glycine/analogs & derivatives , Glycine/therapeutic use , Guanidines/therapeutic use , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Myocardial Reperfusion Injury/drug therapy , Phosphorylation , Piperazines/therapeutic use , Purines/therapeutic use , Rats , Ribosomal Protein S6 Kinases, 90-kDa/metabolism , Sildenafil Citrate , Sulfhydryl Compounds/therapeutic use , Sulfones/therapeutic use , Thiobarbituric Acid Reactive Substances/analysis , Vasodilator Agents/therapeutic use
12.
Rev. méd. Chile ; 138(10): 1246-1252, oct. 2010. graf, tab
Article in Spanish | LILACS | ID: lil-572935

ABSTRACT

Background: Glycine inhibits the formation of advanced glycation end products that may cause central and peripheral neuronal damage, affecting also the auditory nerve. Aim: To evaluate the effect of glycine on auditory nerve conduction and hearing level among patients with type 2 diabetes mellitus and auditory neuropathy. Material and Methods: Twenty grams of oral glycine per day were administered during 6 months to 28 type 2 diabetic patients aged 58 ± 6 years, with auditory pathway neuropathy. Hearing tests and evoked otoacustic potentials were performed regularly. Fifteen diabetic patients aged 49 ± 8 years, without auditory nerve neuropathy did not receive glycine and were followed as a control group. Results: Among patients receiving glycine, a significant improvement in left ear audiometry at 125, 250 and 500 Hz and right ear audiometry at 500 Hz, was observed. Waves I, III and V (p= 0.02) of evoked otoacustic potentials improved significantly in the left ear and wave I in the right ear. Among controls, waves V and III of evoked otoacoustic potentials had a significant impairment in the left ear. Conclusions: There was an improvement in auditory evoked potentials in patients receiving glycine and an impairment in untreated control patients.


Subject(s)
Female , Humans , Male , Middle Aged , Auditory Pathways/drug effects , /complications , Diabetic Neuropathies/therapy , Evoked Potentials, Auditory/drug effects , Glycine Agents/therapeutic use , Glycine/therapeutic use , Audiometry , Auditory Pathways/pathology , Auditory Pathways/physiopathology , Diabetic Neuropathies/physiopathology
13.
Rev Med Chil ; 138(10): 1246-52, 2010 Oct.
Article in Spanish | MEDLINE | ID: mdl-21279270

ABSTRACT

BACKGROUND: Glycine inhibits the formation of advanced glycation end products that may cause central and peripheral neuronal damage, affecting also the auditory nerve. AIM: To evaluate the effect of glycine on auditory nerve conduction and hearing level among patients with type 2 diabetes mellitus and auditory neuropathy. MATERIAL AND METHODS: Twenty grams of oral glycine per day were administered during 6 months to 28 type 2 diabetic patients aged 58 ± 6 years, with auditory pathway neuropathy. Hearing tests and evoked otoacustic potentials were performed regularly. Fifteen diabetic patients aged 49 ± 8 years, without auditory nerve neuropathy did not receive glycine and were followed as a control group. RESULTS: Among patients receiving glycine, a significant improvement in left ear audiometry at 125, 250 and 500 Hz and right ear audiometry at 500 Hz, was observed. Waves I, III and V (p= 0.02) of evoked otoacustic potentials improved significantly in the left ear and wave I in the right ear. Among controls, waves V and III of evoked otoacoustic potentials had a significant impairment in the left ear. CONCLUSIONS: There was an improvement in auditory evoked potentials in patients receiving glycine and an impairment in untreated control patients.


Subject(s)
Auditory Pathways/drug effects , Diabetes Mellitus, Type 2/complications , Diabetic Neuropathies/therapy , Evoked Potentials, Auditory/drug effects , Glycine Agents/therapeutic use , Glycine/therapeutic use , Audiometry , Auditory Pathways/pathology , Auditory Pathways/physiopathology , Diabetic Neuropathies/physiopathology , Female , Humans , Male , Middle Aged
14.
Biomed Pharmacother ; 64(8): 534-40, 2010 Oct.
Article in English | MEDLINE | ID: mdl-19864106

ABSTRACT

Obesity is widely recognized as cause of metabolic syndrome and cardiovascular disease. It is provoked by imbalance between the spending and consumption of energy associated with a chronic inflammatory condition due to excessive storage of fat tissue. Obese patients have an impaired inflammatory profile that contributes to the development of vascular complications, with fat tissue being partially responsible for controlling both processes: energy balance (through PPAR) and inflammatory condition (through inflammatory markers). White adipose tissue produces cytokines (IL-6, TNF-α, resistin, adiponectin, etc.) and participates in a broad spectrum of processes. Recently, glycine has been reported to have anti-inflammatory properties which reduce TNF-α and IL-6 levels and increase adiponectin in 3T3-L1 adipocytes and in fat tissue of obese mice. In this study, the possible regulatory role of glycine on some factors involved in storage and energy burning (PPAR-γ, PPAR-α, PPAR-δ and UCP-2) was analyzed in lean and monosodium glutamate-induced obese mice (MSG/Ob mice). Glycine clearly increased fat tissue PPAR-γ expression in lean but not in MSG/Ob mice. The PPAR-γ and PPAR-α liver expression was repressed in both groups of mice, while the expression of PPAR-δ decreased only in lean mice. Interestingly, glycine treatment also suppressed the expression of UCP-2, TNF-α and IL-6 in lean mice, and increased adiponectin and insulin serum levels. In conclusion, glycine regulates the production of inflammatory cytokines through PPAR-γ. These results provide clues on glycine signaling mechanisms as an anti-inflammatory agent that might be useful for treatment of metabolic and vascular complications associated to inflammation in obesity.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Cytokines/metabolism , Energy Metabolism/drug effects , Glycine/therapeutic use , Ion Channels/metabolism , Mitochondrial Proteins/metabolism , Obesity/prevention & control , Peroxisome Proliferator-Activated Receptors/metabolism , Adipose Tissue/drug effects , Adipose Tissue/immunology , Adipose Tissue/metabolism , Animals , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/pharmacology , Disease Models, Animal , Glycine/administration & dosage , Glycine/pharmacology , Insulin/blood , Interleukin-6/metabolism , Leptin/blood , Mice , Obesity/immunology , Obesity/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Sodium Glutamate , Tumor Necrosis Factor-alpha/metabolism , Uncoupling Protein 2
15.
Nutrition ; 24(7-8): 663-8, 2008.
Article in English | MEDLINE | ID: mdl-18499399

ABSTRACT

OBJECTIVES: Postgastrectomy iron deficiency anemia has a variable prevalence and occurs in 20-50% of patients. Food fortification reports examining ferrous glycinate chelate have shown that it can be 2.5-3.4 times more bioavailable than ferrous sulfate, with minimal gastrointestinal symptoms. The present study was designed as a controlled experimental study including 18 gastrectomized patients with iron deficiency anemia to compare the effects of ferrous sulfate and ferrous glycinate chelate in the treatment of anemia and to evaluate the presence of side effects. METHODS: Patients were divided in two groups: group 1 received ferrous sulfate (200 mg twice a day, corresponding to 80 mg of elemental iron) and group 2 received ferrous glycinate chelate (250 mg/d, corresponding to 50 mg of elemental iron) for 4 mo. Laboratory measurements were performed at baseline and after 2 and 4 mo. RESULTS: Group 1 showed an apparent recovery in laboratory parameters, with increases in medium corpuscular hemoglobin (P = 0.02), serum iron (P = 0.02), and ferritin (P = 0.04), and a decrease in transferrin (P = 0.002) after 4 mo. Individualized analysis showed that only one patient using ferrous sulfate had anemia at the end of the study in contrast to six patients using ferrous glycinate. In addition, ferritin levels increased above 20 microg/L at the end of the study in seven patients using ferrous sulfate in contrast to one patient using ferrous glycinate. CONCLUSION: Patients with iron deficiency anemia after gastrectomy treated with ferrous sulfate had better results in hematologic laboratory parameters than those who used ferrous glycinate chelate.


Subject(s)
Anemia, Iron-Deficiency/drug therapy , Ferrous Compounds/pharmacokinetics , Gastrectomy/adverse effects , Glycine/analogs & derivatives , Iron Chelating Agents/pharmacokinetics , Aged , Biological Availability , Female , Ferritins/blood , Ferrous Compounds/therapeutic use , Glycine/pharmacokinetics , Glycine/therapeutic use , Hemoglobins/metabolism , Humans , Intestinal Absorption , Iron/blood , Iron Chelating Agents/therapeutic use , Male , Middle Aged , Nutritional Status , Treatment Outcome
16.
Int J Colorectal Dis ; 22(12): 1523-9, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17690894

ABSTRACT

BACKGROUND AND AIMS: Radiotherapy is frequently used for cancer treatment, but it may be associated with several complications. Thus, this study aimed to evaluate the role of L-glutamine and/or glycine supplementation on the colonic wall in rats submitted to abdominal radiation. MATERIALS AND METHODS: Sixty adult Wistar rats were randomly divided into six groups: I-healthy, II (control)-irradiated rats without amino acid supplementation, III-irradiated rats with glycine supplementation, IV-irradiated rats with L-glutamine supplementation, V-irradiated rats with glycine supplementation 7 days before irradiation and with L-glutamine supplementation 7 days after irradiation, and VI-irradiated rats with L-glutamine supplementation 7 days before irradiation and with glycine supplementation 7 days after irradiation. Abdominal irradiation was employed with a dose of 1,000 cGy on the eighth day of the experiment. All animals underwent laparotomy on the 15th day for resection of a colonic segment for stereologic analysis. Parametric and nonparametric tests were used for statistical analysis, with the level of significance set at p

Subject(s)
Colon/drug effects , Glutamine/pharmacology , Glycine/pharmacology , Radiation Injuries, Experimental/prevention & control , Radiation-Protective Agents/pharmacology , Animals , Colon/pathology , Colon/radiation effects , Glutamine/therapeutic use , Glycine/therapeutic use , Intestinal Mucosa/drug effects , Intestinal Mucosa/pathology , Intestinal Mucosa/radiation effects , Male , Radiation Injuries, Experimental/etiology , Radiation Injuries, Experimental/pathology , Radiation-Protective Agents/therapeutic use , Radiotherapy/adverse effects , Rats , Rats, Wistar , Time Factors
17.
J Pediatr Gastroenterol Nutr ; 44(3): 365-74, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17325559

ABSTRACT

OBJECTIVE: We examined the effect of a diet supplemented with alanyl-glutamine (AG) or placebo glycine (G) on intestinal barrier function and growth in children in northeastern Brazil. PATIENTS AND METHODS: One hundred seven children ages 7.9 to 82.2 months with a weight-for-age (WAZ), height-for-age (HAZ), or weight-for-height (WHZ) z-score less than -1 were studied. From July 2003 to November 2004, 51 study patients received AG (24 g/d) and 56 received G (25 g/d; isonitrogenic concentration) control for 10 days. Lactulose/mannitol excretion ratio was used as a measure of intestinal permeability and was performed on days 1 and 10 of nutritional supplementation. Weight and height were measured on days 1, 10, 30, and 120 of the protocol. RESULTS: The patients were similar on admission with regard to age, sex, birth weight, nutritional status, lactulose/mannitol ratio, and serum concentrations of glutamine and arginine. The percentage of lactulose urinary excretion significantly improved (decreased) in children receiving AG for 10 days but not in those receiving glycine controls. AG significantly increased cumulative change over 120 days in WHZ and WAZ scores but not HAZ scores after adjustment for age and season in comparison with the placebo glycine group. CONCLUSIONS: Children tolerated AG-supplemented enteral formula well, and it significantly improved cumulative WHZ and WAZ over 120 days in comparison with children in the placebo glycine group. The data also suggested a beneficial effect of AG in the barrier function paracellular pathway, albeit with reduced mannitol excretion. Thus, although the effect of AG on reduced mannitol concentration requires clarification, AG appears to improve nutrition and barrier function.


Subject(s)
Dietary Supplements , Dipeptides/therapeutic use , Intestinal Mucosa/metabolism , Wasting Syndrome/diet therapy , Brazil , Child , Child Development/physiology , Child, Preschool , Developed Countries , Double-Blind Method , Female , Glycine/therapeutic use , Humans , Infant , Intestinal Absorption/physiology , Jejunum/metabolism , Male , Nutrition Disorders/diet therapy , Nutritional Sciences , Permeability , Prospective Studies , Urban Population
18.
Rev Alerg Mex ; 53(6): 212-6, 2006.
Article in English | MEDLINE | ID: mdl-17361755

ABSTRACT

BACKGROUND: Hyperglycemia induces protein glycation, disturbing its function, additionally, the glycated products (AGEs) induce by themselves proinflammatory cytokine release that are responsible for insulin resistance. Glycine has been successfully used in diabetic patients to competitively reduce hemoglobin glycation. OBJECTIVES: To assess hyperglycemia impact on the immune response and to evaluate if it is possible to reverse it by means of glycine administration. MATERIAL AND METHODS: Streptozotocin-induced diabetic rats, with and without glycine administration were challenged with sheep red blood cells, and specific antibody producing cells were accounted. Normal rats were challenged as controls. RESULTS: Induced diabetes modifies significantly the humoral immune response capacity versus sheep red blood cells. Also, glycine administration prevents against this deleterious effect. CONCLUSIONS: Glycine could be an important therapeutic resource among diabetics to avoid the characteristic immunodeficiencies of this disease.


Subject(s)
Antibody Formation/drug effects , Diabetes Mellitus, Experimental/immunology , Glycine/therapeutic use , Immunologic Deficiency Syndromes/drug therapy , Animals , Antibody-Producing Cells/drug effects , Antibody-Producing Cells/immunology , Blood Glucose/analysis , Diabetes Mellitus, Experimental/complications , Drug Evaluation, Preclinical , Erythrocytes/immunology , Glycated Hemoglobin/analysis , Glycation End Products, Advanced/analysis , Glycine/pharmacology , Immunologic Deficiency Syndromes/etiology , Male , Rats , Rats, Wistar , Sheep , Streptozocin
19.
Biol Trace Elem Res ; 104(3): 269-73, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15930596

ABSTRACT

Fortification of a Petit Suisse cheese with zinc sulfate and zinc gluconate stabilized with glycine was used as a tool to overcome zinc-deficiency effects on total-body growth and skeletal growth. Animals were divided in 4 groups of 10 rats: basal (B), control (C), depletion-repletion 1 (DR1), and depletion-repletion 2 (DR2). These four groups were fed with four diets: basal (2 ppm Zn), control (30 ppm Zn), DR1, and DR2; they received a basal diet for 14 d and a control diet for the other 14 d of the experiment, using zinc sulfate for DR1 and zinc gluconate stabilized with glycine for DR2. After 28 d of the experiment, total-body weight and weight gain of the control and DR1 and DR2 animals were not statistically different (p<0.05), Femur weight and femur zinc content of DR1 and DR2 did not achieve the values of control animals (p<0.05), but they were higher than that of basal animals. Our results show that restoration of dietary zinc levels by means of food fortification normalized weight gain, as an indicator of total-body growth, and presented a trend to normalize bone weight, as a marker of skeletal growth, in young rats and independently of the zinc source used.


Subject(s)
Cheese , Deficiency Diseases/diet therapy , Food, Fortified , Zinc Sulfate/therapeutic use , Zinc/deficiency , Animals , Femur/anatomy & histology , Femur/chemistry , Gluconates/therapeutic use , Glycine/therapeutic use , Hematocrit , Hemoglobins/analysis , Male , Rats , Rats, Sprague-Dawley , Weight Gain/drug effects , Zinc/therapeutic use
20.
J Pediatr Gastroenterol Nutr ; 40(1): 28-35, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15625423

ABSTRACT

OBJECTIVE: We examined the effect of standard formula and glutamine or glycine supplemented enteral formula on intestinal permeability and weight gain in children with malnutrition. METHODS: 80 children aged 2 to 60 months with a weight-for-age z-score less than -- 2 were studied. From December 1996 to April 1999, 27 study patients received nonsupplemented formula. From June 2001 to June 2002 an additional 53 patients were randomly assigned to receive formula supplemented with glutamine or glycine (isosmolar concentrations) for 10 days. Lactulose/mannitol excretion ratio was used as a measure of intestinal permeability and was performed before and after 10 days of nutritional rehabilitation. Weight was measured before and after treatment. RESULTS: Patients were similar on admission with regard to age, sex, nutritional status and lactulose/mannitol ratio. The lactulose/mannitol ratio significantly improved (decreased) in children receiving formula supplemented with glutamine for 10 days but not in those receiving glycine or nonsupplemented formula. Weight gain occurred during therapy in all groups and was not statistically different among groups. CONCLUSION: Formula supplemented with glutamine improves intestinal barrier function compared with nonsupplemented formula but does not augment weight gain.


Subject(s)
Child Nutrition Disorders/therapy , Enteral Nutrition , Glutamine/therapeutic use , Intestinal Absorption/drug effects , Intestinal Mucosa/metabolism , Child Nutrition Disorders/metabolism , Child, Preschool , Female , Glycine/therapeutic use , Humans , Infant , Intestinal Absorption/physiology , Intestinal Mucosa/drug effects , Lactulose/metabolism , Male , Mannitol/metabolism , Weight Gain/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL